89614-56-2

Basic information

• Product Name: (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE
• Synonyms: (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE
• CAS NO: 89614-56-2
• Molecular Formula: C₁₈H₂₅NO
• Molecular Weight: 271.3972
• Mol File: 89614-56-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE(89614-56-2)
• EPA Substance Registry System: (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE(89614-56-2)

Safety Data

• Hazardous Substances Data: 89614-56-2(Hazardous Substances Data)

Usage

General Description

(R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE, also known as (R)-Nuciferine, is a naturally-occurring alkaloid found in several plant species, including lotus leaves and nelumbo nucifera. It is a psychoactive compound with a wide range of potential pharmacological effects, including anti-obesity, anti-diabetic, and anti-psychotic properties. (R)-Nuciferine has been studied for its potential as a weight-loss supplement, as well as its ability to modulate glucose and lipid metabolism. It has also been investigated for its potential as a novel treatment for schizophrenia and other psychiatric disorders. Overall, (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE shows promise as a multi-faceted therapeutic agent with diverse potential applications in medicine and healthcare.

Upstream product

• 38969-65-2 1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 29144-31-8 (S)-2-Formyl-1-<(4-methoxyphenyl)methyl>-1,2,3,4,5,6,7,8-octahydroispquinoline 
• 2721-62-2 1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 100466-48-6 ((S)-1-tert-Butoxymethyl-2-methyl-propyl)-[1-(3,4,5,6,7,8-hexahydro-1H-isoquinolin-2-yl)-meth-(E)-ylidene]-amine 
• 100466-49-7 ((S)-1-tert-Butoxymethyl-2-methyl-propyl)-[1-[(S)-1-(4-methoxy-benzyl)-3,4,5,6,7,8-hexahydro-1H-isoquinolin-2-yl]-meth-(E)-ylidene]-amine 
• 100466-46-4 N-benzyl-5,6,7,8-tetrahydroisoquinolinium bromide 
• 100466-47-5 N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 30356-07-1 (1S)-1-[(4-methoxyphenyl)methyl]-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 119-65-3 isoquinoline 
• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 

Downstream Products

• 125-73-5 (+)-dextrorphan 
• 852334-50-0 {2-[2-(4-methoxy-phenethyl)-cyclohexyl]-ethyl}-methyl-amine 
• 95367-72-9 {2-[2-(4-methoxy-phenethyl)-cyclohexyl]-ethyl}-dimethyl-amine 
• 102021-29-4 {2-[2-(4-methoxy-styryl)-cyclohex-1-enyl]-ethyl}-dimethyl-amine 

Relevant articles and documents

On the formation of a side product with hexahydroaporphine-like structure in the Grewe cyclization of dextromethorphan

Factors leading to the formation of a hexahydroaporphine-like cyclizing side product were studied systematically for the first time and the ratio of this side product was controlled effectively. To understand better the electronic effect of substrates on the formation of side products, different 1-benzyloctahydroisoquinolines with substituted groups on nitrogen or benzene ring were compared. A plausible mechanism of cyclizing reaction was proposed, and key intermediates as well as transition states were analyzed using DFT calculations.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia.